Two Ways to Replace an Aortic Valve
If you have been diagnosed with severe aortic stenosis — a narrowing of the aortic valve that restricts blood flow from the heart — your physician has likely discussed valve replacement. Twenty years ago, there was only one option: open-heart surgery. Today, there are two fundamentally different approaches, and understanding the differences is critical to making the right decision for your situation.
SAVR (Surgical Aortic Valve Replacement) is the traditional open-heart operation that has been performed for over 60 years. The surgeon opens the chest through a sternotomy, stops the heart, removes the diseased valve, and sews in a new one — either mechanical or bioprosthetic.
TAVR (Transcatheter Aortic Valve Replacement), also called TAVI in some countries, is a minimally invasive procedure introduced in the early 2000s. A compressed bioprosthetic valve is delivered through a catheter — usually inserted through the femoral artery in the groin — and expanded inside the diseased native valve, pushing it aside.
Both procedures effectively treat aortic stenosis. The question is which one is right for you. Use our risk calculator to understand your surgical risk profile as you consider these options.
When TAVR Is the Better Choice
TAVR was initially developed for patients who were too sick for open-heart surgery. Over two decades, the evidence has expanded dramatically, and TAVR is now approved and recommended across a broad range of patient profiles:
High-Risk and Extreme-Risk Patients
For patients with an STS score above 8%, TAVR is generally the preferred approach. The PARTNER 1 trial demonstrated that TAVR was superior to medical therapy in inoperable patients (who had no surgical option) and non-inferior to surgery in high-risk patients. For extreme-risk patients, TAVR may be the only viable intervention.
Elderly Patients
Patients over 80 tend to benefit significantly from avoiding sternotomy, cardiopulmonary bypass, and the prolonged recovery associated with open-heart surgery. TAVR patients are typically walking within hours of the procedure and discharged within 1–3 days, compared to 5–10 days for SAVR.
Frail Patients
Frailty — characterized by weakness, weight loss, slow walking speed, and reduced physiologic reserve — is a powerful predictor of poor surgical outcomes that is not fully captured by STS or EuroSCORE risk models. Frail patients overwhelmingly do better with TAVR.
Hostile Chest
Patients who have had previous cardiac surgery (especially prior sternotomy), chest radiation therapy, or porcelain aorta (heavy aortic calcification) face significantly higher surgical risk from reopening the chest. TAVR avoids the chest entirely.
Intermediate-Risk Patients
The PARTNER 2 and SAPIEN 3 trials demonstrated that TAVR was non-inferior to surgery in intermediate-risk patients (STS score 4–8%). Five-year follow-up data has been favorable, and many Heart Teams now recommend TAVR for intermediate-risk patients with suitable anatomy.
When Surgery (SAVR) Is the Better Choice
Despite TAVR's expansion, there are important clinical scenarios where traditional surgery remains the gold standard:
Low-Risk, Younger Patients
The Evolut Low Risk and PARTNER 3 trials showed that TAVR was non-inferior to surgery even in low-risk patients at two years. However, long-term data beyond 5–10 years is still maturing. For a 55-year-old patient expected to live another 25–30 years, the proven 20+ year durability track record of surgical bioprosthetic valves (and the lifetime durability of mechanical valves) remains a significant advantage.
The critical question for younger patients is: will the TAVR valve last long enough, or will you need a second procedure (valve-in-valve TAVR or surgical explant) down the road?
Bicuspid Aortic Valves
Approximately 50% of patients undergoing aortic valve replacement for aortic stenosis have a bicuspid (two-leaflet) rather than tricuspid (three-leaflet) valve. Bicuspid anatomy is more variable, often asymmetric, and can present challenges for TAVR deployment including elliptical annuli and heavy, asymmetric calcification. While TAVR in bicuspid valves is increasingly performed at experienced centers, surgery remains the standard recommendation for most bicuspid patients.
Concomitant Cardiac Disease
If you need more than just a valve replacement, surgery may be the better approach. Common scenarios include:
- Aortic stenosis + coronary artery disease — SAVR can be combined with CABG in a single operation
- Aortic stenosis + mitral regurgitation — Combined valve surgery addresses both problems
- Aortic root dilation — Patients with ascending aortic aneurysm need surgical repair that TAVR cannot provide
- Active endocarditis — Infected valves generally require surgical excision and debridement
Vascular Access Limitations
TAVR requires a route for catheter delivery. The preferred approach is transfemoral (through the groin artery). If the femoral arteries are too small, too calcified, or too tortuous, alternative access sites (subclavian, transaortic, transapical, or transcaval) can be used — but each adds complexity and risk. In some cases, severe peripheral vascular disease makes TAVR technically unfeasible.
Anatomy Matters: Key Considerations
Beyond risk scores, your specific anatomy plays a major role in determining the best approach:
- Annular size — TAVR valves come in specific sizes. If your annulus is very small or very large, sizing may be suboptimal
- Coronary height — Low-lying coronary arteries can be obstructed by a TAVR valve, a rare but potentially fatal complication
- Aortic calcification pattern — Heavy, bulky, asymmetric calcification can interfere with TAVR valve seating and increase paravalvular leak
- Left ventricular outflow tract (LVOT) calcification — Calcification below the valve increases the risk of annular rupture during TAVR
This is why pre-procedural CT imaging is mandatory for TAVR evaluation and why the decision should be made by a Heart Team — not a single physician.
Recovery Comparison
The recovery difference between TAVR and SAVR is dramatic:
- Hospital stay: TAVR 1–3 days vs. SAVR 5–10 days
- Return to normal activity: TAVR 1–2 weeks vs. SAVR 6–12 weeks
- Driving: TAVR 1–2 weeks vs. SAVR 4–6 weeks (sternotomy precautions)
- Pain: TAVR involves a small groin incision vs. SAVR requires a full or partial sternotomy
- Rehabilitation: Most TAVR patients do not require formal cardiac rehab; SAVR patients typically do
- Blood transfusion: Significantly less common with TAVR
For elderly or frail patients, the shorter recovery alone can be the deciding factor. A 10-day hospitalization with prolonged bed rest carries its own risks — deconditioning, hospital-acquired infections, delirium — that TAVR largely avoids.
Long-Term Data: What the Trials Show
The evidence base for TAVR continues to mature:
- PARTNER 1 (high/extreme risk): 5-year data showed equivalent mortality between TAVR and SAVR in high-risk patients
- PARTNER 2 (intermediate risk): 5-year data showed similar outcomes, with TAVR showing lower rates of acute kidney injury and atrial fibrillation
- PARTNER 3 (low risk): 2-year data showed TAVR was non-inferior to surgery, though longer follow-up is ongoing
- Evolut Low Risk: 2-year data confirmed non-inferiority of self-expanding TAVR in low-risk patients
The key unanswered question remains valve durability. Surgical bioprosthetic valves have 15–20 year durability data. TAVR valves, by the nature of when they were introduced, have robust data only out to 8–10 years. Early signals suggest TAVR valve durability is comparable, but definitive long-term data for low-risk, younger patients is still being collected.
Questions to Ask Your Heart Team
If you are deciding between TAVR and SAVR, bring these questions to your consultation:
- What is my STS score, and how does it affect the recommendation?
- Am I a candidate for both TAVR and SAVR, or only one?
- If you are recommending TAVR, what is the planned access route?
- What is the expected durability of the valve you would use?
- If the TAVR valve fails in 10–15 years, what are my options then?
- Do I have bicuspid anatomy, and how does that affect the decision?
- Do I have other cardiac conditions that should be addressed at the same time?
- What is your center's volume and outcomes for the recommended procedure?
Get an Independent Assessment
The TAVR vs. SAVR decision is one of the most consequential choices in cardiac care. If you have been told you need aortic valve replacement and want an independent, expert perspective on which approach is right for your anatomy and risk profile, WhiteGloveMD can help. Request an aortic valve second opinion, use our risk calculator to understand your surgical risk, or learn more about our approach to aortic stenosis management.